Navigation Links
Anadys Announces Issuance of U.S. Patent Covering Setrobuvir (ANA598)
Date:6/1/2011

, setrobuvir (ANA598) is being tested in combination with Pegasys® and Copegus® in both treatment-naive patients and patients who failed a prior course of therapy with interferon and ribavirin.  Dosing is underway and approximately 275 patients are expected to be enrolled in the study.  The primary endpoint of the study is Sustained Virological Response 24 weeks after patients complete treatment, known as SVR24.  The Company expects to receive antiviral response data through 12 weeks for all patients, including the 8 week timepoint used for response-guided therapy in treatment-naive patients, in the third quarter of 2011.  Antiviral response data through 24 weeks are expected in the fourth quarter of 2011.  

Prior Clinical and Preclinical Profile of Setrobuvir (ANA598)

In an earlier Phase IIa study, setrobuvir (ANA598) demonstrated potent antiviral activity, as well as good safety and tolerability in combination with interferon and ribavirin through 12 weeks of dosing in treatment-naive genotype 1 HCV patients.  In a completed Phase I study, setrobuvir demonstrated potent antiviral activity in a three day monotherapy study in treatment-naive genotype 1 patients.  To date, setrobuvir has demonstrated an excellent resistance profile in HCV patients.

Setrobuvir (ANA598) has also been characterized in a variety of preclinical studies.  In completed long-term chronic toxicology tests in both rats and monkeys, the No Observed Adverse Effect Level, or NOAEL, was 1000 mg/kg, the highest dose tested.  Data from preclinical models of antiviral activity have laid the foundation for clinical investigation of setrobuvir (ANA598) in DAA combinations.  In particular, synergistic antiviral activity in vitro was observed when setrobuvir (ANA598) was combined with a number of approved or investigational HCV agents, and in vitro combinations of setrobuvir (ANA598) with other DAAs from
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anadys Pharmaceuticals Reports First Quarter 2011 Financial Results and Highlights
2. Anadys Pharmaceuticals Appoints Barry Labinger to Its Board of Directors
3. Anadys Pharmaceuticals to Present at the Cowen & Company Healthcare Conference
4. Anadys Pharmaceuticals to Report Fourth Quarter and Year-end 2010 Financial Results
5. Anadys Pharmaceuticals to Present at the Bio CEO & Investor Conference
6. Anadys Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference
7. Anadys Pharmaceuticals Initiates Phase IIb Study of ANA598 in HCV Patients
8. Anadys Pharmaceuticals Reports Third Quarter 2010 Financial Results and Highlights
9. Anadys Pharmaceuticals to Report Third Quarter 2010 Financial Results
10. Anadys Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
11. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... , Nov. 21, 2014 Statistics released ... and drunk driving increase astronomically during the holidays, beginning ... in many cities. The data, ... Monitoring Systems as part of their annual ... paints a picture of high-risk drinking and increased rates ...
(Date:11/22/2014)... HILL, N.C. , Nov. 21, 2014 /PRNewswire/ ... healthcare system. Undoubtedly, the growing influence of patients ... spend for marketing interactions. Now, more than ever, ... retain patients for medical products is essential. ... firm, Best Practices, LLC, benchmarked companies spent about ...
(Date:11/21/2014)...  Tandem Diabetes Care ® , Inc. (NASDAQ: ... and manufacturer of the t:slim ® Insulin ... non-profit dedicated to improving diabetes therapy management by ... diabetes data accessibility. This partnership will enable users ... development, to download and access data from their ...
Breaking Medicine Technology:Alarming Stats Show Holiday Drinking an Issue for Many 2New Report Details Importance of Adopting a "Patient Journey" Framework in Marketing 2Tandem Diabetes Care Announces Partnership with Tidepool to Further Expand Access to Diabetes Device Data 2Tandem Diabetes Care Announces Partnership with Tidepool to Further Expand Access to Diabetes Device Data 3
(Date:11/24/2014)... 2014 The Mesothelioma Applied Research ... International Symposium on Malignant Mesothelioma from March 2nd through ... sessions will take place on the campus of the ... a community dinner and an awards ceremony, will be ... cover a range of topics about pleural and peritoneal ...
(Date:11/24/2014)... Dallas, TX (PRWEB) November 24, 2014 ... ADP ribose polymerase (PARP) and is one of the ... genetically vulnerable to creating some types of melanoma, and ... but this also sometimes gives their malignancies a exclusive ... on PARP to fix their DNA and allow them ...
(Date:11/24/2014)... The typical American diet includes foods ... Consistently consuming a diet high in calories and carbohydrates ... fat that typically accumulate around the internal organs exposing ... head in the form of love handles, beer bellies ... decision to rid themselves of the burden of embarrassing, ...
(Date:11/24/2014)... November 24, 2014 "My friend was ... trying to cross the street in his motorized wheelchair," ... saw him. I came up with this idea so ... night." , He developed the Safety Lites to make ... low-lighting conditions. The device ensures that motorists can see ...
(Date:11/23/2014)... Tbdress.com has recently announced that its ... 28, 2014. The special offer will provide ladies many gorgeous ... of the world’s largest women’s dresses retailers, and its shoes ... enjoy great discounts on that day: Everything at Tbdress.com is ... orders above $89). , People can use the following coupon ...
Breaking Medicine News(10 mins):Health News:2015 International Symposium on Malignant Mesothelioma Will Take Place at the National Institutes of Health Campus 2Health News:2015 International Symposium on Malignant Mesothelioma Will Take Place at the National Institutes of Health Campus 3Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 2Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 3Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 4Health News:Ketogenic Diet is the Perfect Solution for Diet Doc Patients Who Want to Learn How to Lose Weight over the Holidays 2Health News:Ketogenic Diet is the Perfect Solution for Diet Doc Patients Who Want to Learn How to Lose Weight over the Holidays 3Health News:Ketogenic Diet is the Perfect Solution for Diet Doc Patients Who Want to Learn How to Lose Weight over the Holidays 4Health News:Tbdress.com Special Friday Shoes Sales Online Now 2
... become teenagers, it may be more challenging to regularly include ... heading off such problems as eating disorders, obesity, and inadequate ... professor of human development and family studies and director of ... belief is that teens don,t want to be around their ...
... 12 (HealthDay News) -- Researchers seeking a way to beat ... is altered in a significant number of ovarian tumors, according ... of Project Achilles, a comprehensive effort by scientists from the ... Institute to identify weaknesses in cancers. After analyzing ...
... The UT Family Medicine Associates clinic in the Texas ... National Committee for Quality Assurance (NCQA) as a model ... Physicians, the medical group practice of The University of ... UT Family Medicine Associates was designated a NCQA ...
... Qualified nurses can now have the very latest advanced practice ... of The Royal Marsden Hospital Manual of Clinical Nursing Procedures. ... been launched, has an exciting new format that organises 19 ... It provides four extra chapters on advanced practice procedures ...
... older, and the number of people with dementia is ... still mostly unknown. However, researchers assume that factors such ... as inflammation accelerate aging. But, vice versa, there are ... protect the brain from degenerating, or repair defective structures. ...
... in developing countries, where oversight is lower than in ... the Pew Health Group. The U.S. Food and ... and 80 percent of active ingredients and bulk chemicals ... The white paper, After Heparin: Protecting Consumers from the ...
Cached Medicine News:Health News:Family meals remain important through teen years, expert says 2Health News:Scientists Spot Possible Target in Ovarian Cancer 2Health News:National quality committee recognizes UT family medicine clinic in TMC 2Health News:Professional edition of leading nurse manual launched after rave reviews on new format 2Health News:Bodyguard for the brain 2Health News:Pew finds serious gaps in oversight of US drug safety 2Health News:Pew finds serious gaps in oversight of US drug safety 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: